Canola Oil Multicentre Intervention Trial

NCT01351012 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2014-02-19

No results posted yet for this study

Summary

The purpose of the study is to examine how the consumption of different dietary oil varieties affects a broad range of metabolic responses that are important in the development of cardiovascular diseases. This study will examine the relationship between dietary oil consumption and arterial function, blood fat content, and blood markers of cardiovascular disease risk. Additionally, the efficiency of the body in converting fat from dietary oils into other specific fat compounds with know health benefits will be examined. Also, the correlation between psychosocial parameters and vascular function will be studied.

Conditions

  • Metabolic Syndrome

Interventions

OTHER

Corn and safflower oil

The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks

OTHER

Canola oil

The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks

OTHER

High oleic acid canola oil

The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks

OTHER

DHA enriched high oleic acid canola oil

The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks

OTHER

Flax and safflower oil

The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks

Sponsors & Collaborators

  • University of Toronto

    collaborator OTHER
  • Penn State University

    collaborator OTHER
  • Laval University

    collaborator OTHER
  • University of Manitoba

    lead OTHER

Principal Investigators

  • Peter JH Jones, PhD · University of Manitoba

  • David Jenkins, PhD · University of Toronto

  • Penny Kris-Etherton, PhD, RD · Penn State University

  • Sheila West, PhD · Penn State University

  • Benoit Lamarche, PhD · Laval University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-03-31
Completion
2012-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01351012 on ClinicalTrials.gov